Polyphenols: Anti-Platelet Nutraceutical?

Valeria Ludovici1, Jens Barthelmes1, Matthias P Nagele1

  • 1Cardiology, University Heart Center, University Hospital and University of Zurich, Zurich, Switzerland.

Insights

Dietary polyphenols, particularly flavanols from cocoa and berries, can inhibit platelet activation and aggregation, potentially reducing cardiovascular risk. Further research is needed to determine optimal dosages for therapeutic effects.

Area of Science:

  • Cardiovascular research
  • Nutritional science
  • Pharmacology

Background:

  • Coronary artery disease (CAD) is a chronic condition exacerbated by genetic factors and lifestyle risks, leading to endothelial dysfunction and cardiovascular events.
  • Oxidative stress, inflammation, and platelet hyperactivity are key contributors to plaque formation and atherothrombotic events in CAD.
  • Inhibiting platelet hyperactivity is a potential strategy to mitigate atherothrombotic risk, with dietary interventions showing promise.

Purpose of the Study:

  • To investigate the potential of dietary polyphenols in reducing platelet hyperactivity and hypercoagulability.
  • To explore the complementary anti-platelet therapeutic effects of plant-derived polyphenols.
  • To systematically review existing literature on the topic.

Main Methods:

  • Systematic review of relevant scientific publications.
  • Analysis of in vitro and in vivo studies on polyphenol effects on platelet function.
  • Evaluation of evidence for polyphenol impact on platelet aggregation and signaling pathways.

Main Results:

  • Polyphenol supplementation demonstrated effects on platelet aggregation and function, including antioxidant activity and inhibition of platelet activation pathways.
  • In vitro studies showed polyphenols neutralize free radicals, inhibit platelet activation, block thromboxane A2 receptors, and enhance nitric oxide production.
  • In vivo data on dietary polyphenols' effects on platelet aggregation are limited and sometimes conflicting, with flavanols showing consistent efficacy.

Conclusions:

  • Dietary polyphenols, especially flavanols in cocoa and berries, reduce platelet activation and aggregation through various mechanisms.
  • Further controlled interventional studies are necessary to establish effective dosages and circulating concentrations for anti-platelet effects.
  • Polyphenols represent a promising area for complementary therapies in managing cardiovascular health.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.9K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
380
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K